Analysis of Clinical Efficacy and Safety of Flumatinib in the Treatment of 80 Cases of Chronic Myeloid Leukemia
Objective:To analyze the clinical efficacy and safety of flumatinib in the treatment of chronic myeloid leukemia(CML).Methods:The clinical data of 80 CML patients were selected,and complete hematologic response(CHR),major molecular re-sponse(MMR),complete cytogenetic response(CCyR)were observed at 3 months,6 months and 12 months after treatment.Patients were divided into low risk group,medium risk group and high risk group according to the Sokal score,and the optimal response rate in each group was analyzed.The adverse reactions of patients were recorded.Results:There were significant differences in CHR rate,MMR rate and CCyR rate at 3 months,6 months and 12 months after treatment(P＜0.05).There were significant differences in the optimal response rate between the low risk group,the middle risk group and the high risk group at 3 months,6 months and 12 months after treatment(P＜0.05).Most patients had good tolerance to flumatinib,the main adverse reactions were grade Ⅰ-Ⅲ hematological adverse reactions and grade Ⅰ non-hematological adverse reactions.Conclusion:Flumartinib has a good therapeutic effect and reliable safety in the treatment of CML patients.The patient has good hematological response,molecular response,and cytogenetic response.
NETL
NSTL
万方数据
